|
1.
|
N FerraraRS KerbelAngiogenesis as a
therapeutic
targetNature438967974200510.1038/nature0448316355214
|
|
2.
|
P CarmelietAngiogenesis in health and
diseaseNat Med9653660200310.1038/nm0603-65312778163
|
|
3.
|
AS ChungJ LeeN FerraraTargeting the tumour
vasculature: insights from physiological angiogenesisNat Rev
Cancer10505514201010.1038/nrc286820574450
|
|
4.
|
P CarmelietRK JainMolecular mechanisms and
clinical applications of
angiogenesisNature473298307201110.1038/nature1014421593862
|
|
5.
|
RK JainDG DudaJW ClarkJS LoefflerLessons
from phase III clinical trials on anti-VEGF therapy for cancerNat
Clin Pract Oncol32440200610.1038/ncponc040316407877
|
|
6.
|
H HurwitzL FehrenbacherW
NovotnyBevacizumab plus irinotecan, fluorouracil and leucovorin for
metastatic colorectal cancerN Engl J
Med35023352342200410.1056/NEJMoa03269115175435
|
|
7.
|
LB SaltzS ClarkeE Díaz-RubioBevacizumab in
combination with oxaliplatin-based chemotherapy as first-line
therapy in metastatic colorectal cancer: a randomized phase III
studyJ Clin Oncol2620132019200810.1200/JCO.2007.14.993018421054
|
|
8.
|
NC TebbuttK WilsonVJ GebskiCapecitabine,
bevacizumab and mitomycin in first-line treatment of metastatic
colorectal cancer: results of the Australasian Gastrointestinal
Trials Group Randomized Phase III MAX StudyJ Clin
Oncol2831913198201010.1200/JCO.2009.27.7723
|
|
9.
|
M ReckJ von PawelP ZatloukalPhase III
trial of cisplatin plus gemcitabine with either placebo or
bevacizumab as first-line therapy for nonsquamous non-small-cell
lung cancer: AVAilJ Clin
Oncol2712271234200910.1200/JCO.2007.14.546619188680
|
|
10.
|
A SandlerR GrayMC
PerryPaclitaxel-carboplatin alone or with bevacizumab for
non-small-cell lung cancerN Engl J
Med35525422550200610.1056/NEJMoa06188417167137
|
|
11.
|
J FolkmanTumor angiogenesis: therapeutic
implicationsN Engl J
Med28511821186197110.1056/NEJM1971111828521084938153
|
|
12.
|
S GoelDG DudaL XuNormalization of the
vasculature for treatment of cancer and other diseasesPhysiol
Rev9110711121201110.1152/physrev.00038.201021742796
|
|
13.
|
RK JainNormalization of tumor vasculature:
an emerging concept in antiangiogenic
therapyScience3075862200510.1126/science.110481915637262
|
|
14.
|
LH GrayAD CongerM EbertS HornseyOC
ScottThe concentration of oxygen dissolved in tissues at the time
of irradiation as a factor in radiotherapyBr J
Radiol26638648195310.1259/0007-1285-26-312-63813106296
|
|
15.
|
S OffermannsW RosenthalEncyclopedia of
Molecular Pharmacology2nd
editionSpringer-VerlagBerlin200810.1007/978-3-540-38918-7
|
|
16.
|
C OehlerJA O’DonoghueJ
Russell18F-fluromisonidazole PET imaging as a biomarker
for the response to 5,6-dimethylxanthenone-4-acetic acid in
colorectal xenograft tumorsJ Nucl
Med52437444201110.2967/jnumed.110.081372
|
|
17.
|
M YangH GaoX SunMultiplexed PET probes for
imaging breast cancer early response to VEGF121/rGel
treatmentMol Pharm8621628201110.1021/mp100446t21280671
|
|
18.
|
G TangM WangX TangM GanL LuoFully
automated one-pot synthesis of
[18F]fluoromisonidazoleNucl Med Biol325535582005
|
|
19.
|
SJ OhDY ChiC MosdzianowskiFully automated
synthesis of [18F]fluoromisonidazole using a
conventional [18F]FDG moduleNucl Med
Biol328999052005
|
|
20.
|
S ZhaoY KugeT MochizukiBiologic correlates
of intratumoral heterogeneity in 18F-FDG distribution
with regional expression of glucose transporters and hexokinase-II
in experimental tumorJ Nucl Med46675682200515809491
|
|
21.
|
RS BrownJY LeungSJ FisherKA FreySP
EthierRL WahlIntratumoral distribution of tritiated
fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells
important?J Nucl Med361854186119957562055
|
|
22.
|
H ToyamaM IchiseJS LiowAbsolute
quantification of regional cerebral glucose utilization in mice by
18F-FDG small animal PET scanning and 2-14C-DG
autoradiographyJ Nucl Med4513981405200415299067
|
|
23.
|
EA EisenhauerP TherasseJ BogaertsNew
response evaluation criteria in solid tumours: revised RECIST
guideline (version 1.1)Eur J
Cancer45228247200910.1016/j.ejca.2008.10.026
|
|
24.
|
R Schor-BardachDC AlsopI PedrosaDoes
arterial spin-labeling MR imaging-measured tumor perfusion
correlate with renal cell cancer response to antiangiogenic therapy
in a mouse
model?Radiology251731742200910.1148/radiol.252108105919474376
|
|
25.
|
Z KanS PhongkitkarunS KobayashiFunctional
CT for quantifying tumor perfusion in antiangiogenic therapy in a
rat
modelRadiology237151158200510.1148/radiol.236304129316183931
|
|
26.
|
Y ChangJ AdnaneP TrailSorafenib (BAY
43-9006) inhibits tumor growth and vascularization and induces
tumor apoptosis and hypoxia in RCC xenograft modelsCancer Chemother
Pharmacol59561574200710.1007/s00280-006-0393-417160391
|
|
27.
|
RK JainNormalizing tumor vasculature with
anti-angiogenic therapy: a new paradigm for combination therapyNat
Med7987989200110.1038/nm0901-98711533692
|
|
28.
|
LM ChingD GoldsmithWR JosephH KörnerJD
SedgwickBC BaguleyInduction of intratumoral tumor necrosis factor
(TNF) synthesis and hemorrhagic necrosis by
5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout
miceCancer Res5933043307199910416582
|
|
29.
|
K HoriStarvation tactics for solid tumors:
tumor blood flow interruption via a combretastatin derivative
(Cderiv) and its micro-circulation mechanismCancer Metastasis
Rev31109122201210.1007/s10555-011-9333-922101805
|
|
30.
|
J MarxAngiogenesis. A boost for tumor
starvationScience301452454200310.1126/science.301.5632.45212881543
|
|
31.
|
DM PattersonGJ RustinVascular damaging
agentsClin Oncol (R Coll
Radiol)19443456200710.1016/j.clon.2007.03.014
|
|
32.
|
T ShinojimaM OyaA TakayanagiR MizunoN
ShimizuM MuraiRenal cancer cells lacking hypoxia inducible factor
(HIF)-1alpha expression maintain vascular endothelial growth factor
expression through
HIF-2alphaCarcinogenesis28529536200710.1093/carcin/bgl143
|
|
33.
|
SW EbbinghausMS GordonRenal cell
carcinoma: rationale and development of therapeutic inhibitors of
angiogenesisHematol Oncol Clin North
Am1811431159ixx200410.1016/j.hoc.2004.06.00315474339
|
|
34.
|
RA FiglinRenal cell carcinoma: management
of advanced diseaseJ
Urol161381387199910.1016/S0022-5347(01)61897-49915408
|
|
35.
|
PA GodleyM TaylorRenal cell carcinomaCurr
Opin Oncol13199203200110.1097/00001622-200105000-0001211307065
|
|
36.
|
X NaG WuCK RyanSR SchoenPA di’SantagneseEM
MessingOverproduction of vascular endothelial growth factor related
to von Hippel-Lindau tumor suppressor gene mutations and
hypoxia-inducible factor-1 alpha expression in renal cell
carcinomasJ Urol170588592200310.1097/01.ju.0000074870.54671.98
|
|
37.
|
J JośkoM MazurekTranscription factors
having impact on vascular endothelial growth factor (VEGF) gene
expression in angiogenesisMed Sci Monit10RA8998200415039660
|
|
38.
|
WG KaelinThe von Hippel-Lindau tumor
suppressor protein and clear cell renal carcinomaClin Cancer
Res13S680S684200710.1158/1078-0432.CCR-06-186517255293
|
|
39.
|
W CáceresA Cruz-ChacónRenal cell
carcinoma: molecularly targeted therapyPR Health Sci
J307377201116336094
|
|
40.
|
TE HutsonTargeted therapies for the
treatment of metastatic renal cell carcinoma: clinical
evidenceOncologist16Suppl
21422201110.1634/theoncologist.2011-S2-1421346036
|
|
41.
|
J SosmanI PuzanovCombination targeted
therapy in advanced renal cell
carcinomaCancer11523682375200910.1002/cncr.2423419402058
|
|
42.
|
SM WilhelmC CarterL TangBAY 43-9006
exhibits broad spectrum oral antitumor activity and targets the
RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor
progression and angiogenesisCancer
Res6470997109200410.1158/0008-5472.CAN-04-144315466206
|
|
43.
|
A JahangiriMK AghiBiomarkers predicting
tumor response and evasion to anti-angiogenic therapyBiochim
Biophys Acta182586100201222067555
|
|
44.
|
A PircherW HilbeI HeideggerJ DrevsA
TichelliM MedingerBiomarkers in tumor angiogenesis and
anti-angiogenic therapyInt J Mol
Sci1270777099201110.3390/ijms1210707722072937
|
|
45.
|
M ZweifelAR PadhaniPerfusion MRI in the
early clinical development of antivascular drugs: decorations or
decision making tools?Eur J Nucl Med Mol Imaging37Suppl
1164182201010.1007/s00259-010-1451-z20461374
|
|
46.
|
JA RaleighDP Calkins-AdamsLH RinkerHypoxia
and vascular endothelial growth factor expression in human squamous
cell carcinomas using pimonidazole as a hypoxia markerCancer
Res583765376819989731480
|
|
47.
|
EG TroostP LavermanJH KaandersImaging
hypoxia after oxygenation-modification: comparing
[18F]FMISO autoradiography with pimonidazole
immunohistochemistry in human xenograft tumorsRadiother
Oncol80157164200616905213
|
|
48.
|
EG TroostP LavermanME
PhilippensCorrelation of [18F] FMISO autoradiography and
pimonidazole [corrected] immunohistochemistry in human head and
neck carcinoma xenograftsEur J Nucl Med Mol
Imaging35180318112008
|
|
49.
|
LM CherC MuroneN LawrentschukCorrelation
of hypoxic cell fraction and angiogenesis with glucose metabolic
rate in gliomas using 18F-fluoromisonidazole,
18F-FDG PET and immunohistochemical studiesJ Nucl
Med47410418200616513609
|
|
50.
|
WJ KohKS BergmanJS RaseyEvaluation of
oxygenation status during fractionated radiotherapy in human
nonsmall cell lung cancers using [F-18]fluoromisonidazole positron
emission tomographyInt J Radiat Oncol Biol
Phys3339139819957673026
|
